Lawsuit filed for Investors who lost money with shares of Charles River Laboratories International, Inc. (NYSE: CRL)

An investor, who purchased shares of Charles River Laboratories International, Inc. (NYSE: CRL), filed a lawsuit over alleged violations of Federal Securities Laws by Charles River Laboratories International, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Charles River Laboratories International, Inc. (NYSE: CRL) have certain options and for certain investors are short and strict deadlines running. Deadline: July 18, 2023. NYSE: CRL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Wilmington, MA based Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. On February 22, 2023, Charles River Laboratories International, Inc. disclosed that it received a subpoena from the Justice Department relating to an ongoing investigation into the supply chain and illegal importation of nonhuman primates for research. The Company has voluntarily suspended shipments of primates from Cambodia. The Company also warned that the decision to suspend shipments will negatively impact its earnings this year and will reduce revenue growth by 200 basis points to 400 basis points.Shares of Charles River Laboratories International, Inc. (NYSE: CRL) declined from $262 per share on February 08, 2023, to $207.01 per share on February 22, 2023.

The plaintiff claims that between May 5, 2020 and February 21, 2023, the Defendants failed to disclose to investors that Charles River had engaged in illegal activity with respect to its importation of non-human primates for research, that, as a result, Charles River was at a heightened risk of criminal and regulatory investigation by, inter alia, the U.S. Department of Justice, that, as a result, Charles River would be forced to suspend shipments of primates from Cambodia, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Charles River Laboratories International, Inc. (NYSE: CRL) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.